Courtroom CM, Ankeny JS, Hou S, Tseng HR, Tomlinson JS. Enhancing pancreatic most cancers prognosis utilizing circulating tumor cells: prospects for staging and single-cell evaluation. Professional Rev Mol Diagn. 2015;15:1491–504.
Neoptolemos JP, Kleeff J, Michl P, Costello E, Greenhalf W, Palmer DH. Therapeutic developments in pancreatic most cancers: present and future views. Nat evaluations Gastroenterol Hepatol. 2018;15:333–48.
Buscail L. Commentary. Pancreatic most cancers: is the worst to come back? Int J Epidemiol. 2017;46:1774–5.
Siegel RL, Miller KD, Jemal A. Most cancers statistics. 2020. CA: a most cancers journal for clinicians. 2020; 70: 7–30.
Kleeff J, Korc M, Apte M, La Vecchia C, Johnson CD, Biankin AV, et al. Pancreatic most cancers. Nat Evaluations Illness Primers. 2016;2:16022.
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. World most cancers statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 international locations. Most cancers J Clin. 2021;71:209–49.
Humphris JL, Chang DK, Johns AL, Scarlett CJ, Pajic M, Jones MD, et al. The prognostic and predictive worth of serum CA19.9 in pancreatic most cancers. Ann Oncol. 2012;23:1713–22.
Zhou B, Xu J-W, Cheng Y-G, Gao J-Y, Hu S-Y, Wang L, et al. Early detection of pancreatic most cancers: The place are we now and the place are we going? J Most cancers. 2017;141:231–41.
Garrido-Laguna I, Hidalgo M. Pancreatic most cancers: from state-of-the-art therapies to promising novel therapies. Nat evaluations Clin Oncol. 2015;12:319–34.
Most cancers statistics of American Most cancers Society. https://www.most cancers.org/most cancers/pancreatic-cancer/about/key-statistics.html. Accessed 20 August 2022.
Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting most cancers incidence and deaths to 2030: the sudden burden of thyroid, liver, and pancreas cancers in the US. Most cancers Res. 2014;74:2913–21.
Siegel RL, Miller KD, Fuchs HE, Jemal A. Most cancers Statistics. 2021. CA: a most cancers journal for clinicians. 2021; 71: 7–33.
Lai X, Wang M, McElyea SD, Sherman S, Home M, Korc M. A microRNA signature in circulating exosomes is superior to exosomal glypican-1 ranges for diagnosing pancreatic most cancers. Most cancers Lett. 2017;393:86–93.
Zhu Y, Zhang H, Chen N, Hao J, Ma XJM. Diagnostic worth of varied liquid biopsy strategies for pancreatic most cancers: A scientific overview and meta-analysis. Med (Baltim). 2020;99:e18581.
Poruk KE, Homosexual DZ, Brown Okay, Mulvihill JD, Boucher KM, Scaife CL, et al. The scientific utility of CA 19 – 9 in pancreatic adenocarcinoma: diagnostic and prognostic updates. Curr Mol Med. 2013;13:340–51.
Ballehaninna UK, Chamberlain RS. The scientific utility of serum CA 19 – 9 within the prognosis, prognosis and administration of pancreatic adenocarcinoma: An proof based mostly appraisal. J Gastrointest Oncol. 2012;3:105–19.
Mellby LD, Nyberg AP, Johansen JS, Wingren C, Nordestgaard BG, Bojesen SE, et al. Serum Biomarker Signature-Based mostly Liquid Biopsy for Analysis of Early-Stage Pancreatic Most cancers. J Clin Oncol. 2018;36:2887–94.
Mayerle J, Kalthoff H, Reszka R, Kamlage B, Peter E, Schniewind B, et al. Metabolic biomarker signature to distinguish pancreatic ductal adenocarcinoma from power pancreatitis. Intestine. 2018;67:128–37.
Mehta S, Bhimani N, Gill AJ, Samra JS, Sahni S, Mittal A. Serum Biomarker Panel for Analysis and Prognosis of Pancreatic Ductal Adenocarcinomas. Entrance Oncol. 2021;11:708963.
Capurso G, Signoretti M, Valente R, Arnelo U, Lohr M, Poley JW, et al. Strategies and outcomes of screening for pancreatic adenocarcinoma in high-risk people. World J Gastrointest endoscopy. 2015;7:833–42.
Baek HW, Park MJ, Rhee YY, Lee KB, Kim MA, Park IA. Diagnostic accuracy of endoscopic ultrasound-guided nice needle aspiration cytology of pancreatic lesions. J Pathol translational Med. 2015;49:52–60.
Kitano M, Yoshida T, Itonaga M, Tamura T, Hatamaru Okay, Yamashita Y. Impression of endoscopic ultrasonography on prognosis of pancreatic most cancers. J Gastroenterol. 2019;54:19–32.
Adamska A, Domenichini A, Falasca M. Pancreatic Ductal Adenocarcinoma: Present and Evolving Therapies. Int J Mol Sci. 2017;18:1338.
Neesse A, Krug S, Gress TM, Tuveson DA, Michl P. Rising ideas in pancreatic most cancers drugs: focusing on the tumor stroma. Onco Targets Ther. 2014;7:33–43.
Xu Z, Pothula SP, Wilson JS, Apte MV. Pancreatic most cancers and its stroma: a conspiracy principle. World J gastroenterology: WJG. 2014;20:11216.
Gu Z, Du Y, Zhao X, Wang C. Tumor microenvironment and metabolic reworking in gemcitabine-based chemoresistance of pancreatic most cancers. Most cancers Lett. 2021;521:98–108.
Zeng S, Pöttler M, Lan B, Grützmann R, Pilarsky C, Yang H. Chemoresistance in Pancreatic Most cancers. Int J Mol Sci. 2019;20:4504.
Théry C, Ostrowski M, Segura E. Membrane vesicles as conveyors of immune responses. Nat Rev Immunol. 2009;9:581–93.
Kalra H, Drummen GPC, Mathivanan S. Deal with Extracellular Vesicles: Introducing the Subsequent Small Huge Factor. Int J Mol Sci. 2016;17:170.
Gurunathan S, Kang M-H, Jeyaraj M, Qasim M, Kim J-H. Overview of the isolation, characterization, organic operate, and multifarious therapeutic approaches of exosomes. Cells. 2019;8:307.
Shao H, Im H, Castro CM, Breakefield X, Weissleder R, Lee H. New Applied sciences for Evaluation of Extracellular Vesicles. Chem Rev. 2018;118:1917–50.
Chang C-H, Pauklin S. Extracellular vesicles in pancreatic most cancers development and therapies. Cell Loss of life Dis. 2021;12:1–12.
Tkach M, Théry C. Communication by Extracellular Vesicles: The place We Are and The place We Must Go. Cell. 2016;164:1226–32.
Kourembanas S. Exosomes. Autos of Intercellular Signaling, Biomarkers, and Vectors of Cell Remedy. Annu Rev Physiol. 2015;77:13–27.
Armstrong EA, Beal EW, Chakedis J, Paredes AZ, Moris D, Pawlik TM, et al. Exosomes in Pancreatic Most cancers: from Early Detection to Remedy. J Gastrointest surgical procedure: official J Soc Surg Aliment Tract. 2018;22:737–50.
De Lellis L, Florio R, Di Bella MC, Brocco D, Guidotti F, Tinari N, et al. Exosomes as pleiotropic gamers in pancreatic most cancers. Biomedicines. 2021;9:275.
Pisitkun T, Shen R-F, Knepper MA. Identification and proteomic profiling of exosomes in human urine. Proc Natl Acad Sci USA. 2004;101:13368.
Bonnerot C, Vincendeau-Scherrer C, Lankar D, Raposo G, Caby M-P. Exosomal-like vesicles are current in human blood plasma. Int Immunol. 2005;17:879–87.
Ogawa Y, Miura Y, Harazono A, Kanai-Azuma M, Akimoto Y, Kawakami H, et al. Proteomic Evaluation of Two Sorts of Exosomes in Human Complete Saliva. Biol Pharm Bull. 2011;34:13–23.
Sharma P, Diergaarde B, Ferrone S, Kirkwood JM, Whiteside TL. Melanoma cell-derived exosomes in plasma of melanoma sufferers suppress features of immune effector cells. Sci Rep. 2020;10:1–11.
Simpson RJ, Lim JWE, Moritz RL, Mathivanan S. Exosomes: proteomic insights and diagnostic potential. Professional Rev Proteomics. 2009;6:267–83.
Choi D-S, Lee J, Go G, Kim Y-Okay, Gho YS. Circulating Extracellular Vesicles in Most cancers Analysis and Monitoring. Mol Diagn Ther. 2013;17:265–71.
Alderton GK. Fishing for exosomes. Nat Rev Most cancers. 2015;15:453.
Zhang W, Jiang L, Diefenbach RJ, Campbell DH, Walsh BJ, Packer NH, et al. Enabling Delicate Phenotypic Profiling of Most cancers-Derived Small Extracellular Vesicles Utilizing Floor-Enhanced Raman Spectroscopy Nanotags. ACS Sens. 2020;5:764–71.
Lu M, Huang Y. Bioinspired exosome-like therapeutics and supply nanoplatforms. Biomaterials. 2020;242:119925.
Jiang L, Gu Y, Du Y, Liu J. Exosomes: diagnostic biomarkers and therapeutic supply automobiles for most cancers. Mol Pharm. 2019;16:3333–49.
Qiao L, Hu S, Huang Okay, Su T, Li Z, Vandergriff A, et al. Tumor cell-derived exosomes dwelling to their cells of origin and can be utilized as Trojan horses to ship most cancers medicine. Theranostics. 2020;10:3474.
Massoumi RL, Hines OJ, Eibl G, King JC. Rising Proof for the Medical Relevance of Pancreatic Most cancers Exosomes. Pancreas. 2019;48:1–8.
Kalluri R, LeBleu VS. The biology, operate, and biomedical purposes of exosomes. Science. 2020;367:eaau6977.
Li W, Li C, Zhou T, Liu X, Liu X, Li X, et al. Function of exosomal proteins in most cancers prognosis. Mol Most cancers. 2017;16:145.
Erb U, Zöller M. Progress and potential of exosome evaluation for early pancreatic most cancers detection. Professional Rev Mol Diagn. 2016;16:757–67.
Tai YL, Chu PY, Lee BH, Chen KC, Yang CY, Kuo WH, et al. Fundamentals and purposes of tumor-derived extracellular vesicles. J Biomed Sci. 2019;26:35.
Zhang Y, Bi J, Huang J, Tang Y, Du S, Li P. Exosome. A Overview of Its Classification, Isolation Strategies, Storage, Diagnostic and Focused Remedy Purposes. Int J Nanomedicine. 2020;15:6917–34.
Qian L, Yu S, Chen Z, Meng Z, Huang S, Wang P. Features and scientific implications of exosomes in pancreatic most cancers. Biochimica et Biophysica Acta (BBA) – Evaluations on Most cancers. 2019; 1871: 75–84.
Zhao G, Zhou A, Li X, Zhu S, Wang Y, Zhang S, et al. The Significance of Exosomal RNAs within the Growth, Analysis, and Remedy of Gastric Most cancers. Genes. 2021;12:73.
Zhao Z, Zhao G, Yang S, Zhu S, Zhang S, Li P. The importance of exosomal RNAs within the improvement, prognosis, and remedy of pancreatic most cancers. Most cancers Cell Int. 2021;21:1–16.
Yee NS, Zhang S, He H-Z, Zheng S-Y. Extracellular Vesicles as Potential Biomarkers for Early Detection and Analysis of Pancreatic Most cancers. 2020; 8: 581.
Xu Y-F, Hannafon BN, Zhao YD, Postier RG, Ding W-Q. Plasma exosome miR-196a and miR-1246 are potential indicators of localized pancreatic most cancers. 2017; 8: 77028–40.
Joshi GK, Deitz-McElyea S, Liyanage T, Lawrence Okay, Mali S, Sardar R, et al. Label-Free Nanoplasmonic-Based mostly Quick Noncoding RNA Sensing at Attomolar Concentrations Permits for Quantitative and Extremely Particular Assay of MicroRNA-10b in Organic Fluids and Circulating Exosomes. ACS Nano. 2015;9:11075–89.
Takahasi Okay, Iinuma H, Wada Okay, Minezaki S, Kawamura S, Kainuma M, et al. Usefulness of exosome-encapsulated microRNA-451a as a minimally invasive biomarker for prediction of recurrence and prognosis in pancreatic ductal adenocarcinoma. 2018; 25: 155–61.
Marin AM, Mattar SB, Amatuzzi RF, Chammas R, Uno M, Zanette DL, et al. Plasma Exosome-Derived microRNAs as Potential Diagnostic and Prognostic Biomarkers in Brazilian Pancreatic Most cancers Sufferers. Biomolecules. 2022;12:769.
Wang C, Wang J, Cui W, Liu Y, Zhou H, Wang Y, et al. Serum Exosomal miRNA-1226 as Potential Biomarker of Pancreatic Ductal Adenocarcinoma. Onco Targets Ther. 2021;14:1441–51.
Que R, Ding G, Chen J, Cao L. Evaluation of serum exosomal microRNAs and clinicopathologic options of sufferers with pancreatic adenocarcinoma. World J Surg Oncol. 2013;11:219.
Verel-Yilmaz Y, Fernández JP, Schäfer A, Nevermann S, Prepare dinner L, Gercke N, et al. Extracellular Vesicle-Based mostly Detection of Pancreatic Most cancers. Frontiers in Cell and Developmental Biology. 2021; 9.
Goto T, Fujiya M, Konishi H, Sasajima J, Fujibayashi S, Hayashi A, et al. An elevated expression of serum exosomal microRNA-191, – 21, – 451a of pancreatic neoplasm is taken into account to be environment friendly diagnostic marker. BMC Most cancers. 2018;18:116.
Madhavan B, Yue S, Galli U, Rana S, Gross W, Müller M, et al. Mixed analysis of a panel of protein and miRNA serum-exosome biomarkers for pancreatic most cancers prognosis will increase sensitivity and specificity. Int J Most cancers. 2015;136:2616–27.
Machida T, Tomofuji T, Maruyama T, Yoneda T, Ekuni D, Azuma T, et al. miR–1246 and miR–4644 in salivary exosome as potential biomarkers for pancreatobiliary tract most cancers. Oncol Rep. 2016;36:2375–81.
Nakamura S, Sadakari Y, Ohtsuka T, Okayama T, Nakashima Y, Gotoh Y, et al. Pancreatic Juice Exosomal MicroRNAs as Biomarkers for Detection of Pancreatic Ductal Adenocarcinoma. Ann Surg Oncol. 2019;26:2104–11.
Hu J, Sheng Y, Kwak KJ, Shi J, Yu B, Lee LJ. A signal-amplifiable biochip quantifies extracellular vesicle-associated RNAs for early most cancers detection. Nat Commun. 2017;8:1683.
Yang Z, LaRiviere MJ, Ko J, Until JE, Christensen T, Yee SS, et al. A Multianalyte Panel Consisting of Extracellular Vesicle miRNAs and mRNAs, cfDNA, and CA19-9 Exhibits Utility for Analysis and Staging of Pancreatic Ductal Adenocarcinoma. 2020; 26: 3248–58.
Lau C, Kim Y, Chia D, Spielmann N, Eibl G, Elashoff D, et al. Function of Pancreatic Most cancers-derived Exosomes in Salivary Biomarker Growth. J Biol Chem. 2013;288:26888–97.
Li Z, Jiang P, Li J, Peng M, Zhao X, Zhang X, et al. Tumor-derived exosomal lnc-Sox2ot promotes EMT and stemness by performing as a ceRNA in pancreatic ductal adenocarcinoma. Oncogene. 2018;37:3822–38.
Takahashi Okay, Ota Y, Kogure T, Suzuki Y, Iwamoto H, Yamakita Okay, et al. Circulating extracellular vesicle-encapsulated HULC is a possible biomarker for human pancreatic most cancers. Most cancers Sci. 2020;111:98–111.
Kumar SR, Kimchi ET, Manjunath Y, Gajagowni S, Stuckel AJ, Kaifi JT. RNA cargos in extracellular vesicles derived from blood serum in pancreas related circumstances. Sci Rep. 2020;10:2800.
Yu S, Li Y, Liao Z, Wang Z, Wang Z, Li Y, et al. Plasma extracellular vesicle lengthy RNA profiling identifies a diagnostic signature for the detection of pancreatic ductal adenocarcinoma. 2020; 69: 540–50.
Li J, Li Z, Jiang P, Peng M, Zhang X, Chen Okay, et al. Round RNA IARS (circ-IARS) secreted by pancreatic most cancers cells and situated inside exosomes regulates endothelial monolayer permeability to advertise tumor metastasis. J Experimental Clin Most cancers Res. 2018;37:177.
Li Z, Yanfang W, Li J, Jiang P, Peng T, Chen Okay, et al. Tumor-released exosomal round RNA PDE8A promotes invasive progress by way of the miR-338/MACC1/MET pathway in pancreatic most cancers. Most cancers Lett. 2018;432:237–50.
Bartel DP. MicroRNAs: goal recognition and regulatory features. Cell. 2009;136:215–33.
Chiang HR, Schoenfeld LW, Ruby JG, Auyeung VC, Spies N, Baek D, et al. Mammalian microRNAs: experimental analysis of novel and beforehand annotated genes. Genes Dev. 2010;24:992–1009.
Zhang X, Xia D, Wang R-X, Zhang Y-T, Zhang S-Y, Yang C, et al. Identification of potential biomarkers for digestive system cancers from serum-derived extracellular vesicle RNA. Clin Chim Acta. 2022;531:36–47.
Liu B, Yang H, Taher L, Denz A, Grützmann R, Pilarsky C, et al. Identification of Prognostic Biomarkers by Mixed mRNA and miRNA Expression Microarray Evaluation in Pancreatic Most cancers. Translational Oncol. 2018;11:700–14.
Gupta RA, Shah N, Wang KC, Kim J, Horlings HM, Wong DJ, et al. Lengthy non-coding RNA HOTAIR reprograms chromatin state to advertise most cancers metastasis. Nature. 2010;464:1071–6.
Costa-Silva B, Aiello NM, Ocean AJ, Singh S, Zhang H, Thakur Basant Okay, et al. Pancreatic most cancers exosomes provoke pre-metastatic area of interest formation within the liver. Nat Cell Biol. 2015;17:816–26.
Chevillet JR, Kang Q, Ruf IK, Briggs HA, Vojtech LN, Hughes SM, et al. Quantitative and stoichiometric evaluation of the microRNA content material of exosomes. Proceedings of the Nationwide Academy of Sciences. 2014; 111: 14888-93.
Kahlert C, Melo SA, Protopopov A, Tang J, Seth S, Koch M, et al. Identification of double-stranded genomic DNA spanning all chromosomes with mutated KRAS and p53 DNA within the serum exosomes of sufferers with pancreatic most cancers. J Biol Chem. 2014;289:3869–75.
Thakur BK, Zhang H, Becker A, Matei I, Huang Y, Costa-Silva B, et al. Double-stranded DNA in exosomes: a novel biomarker in most cancers detection. Cell Res. 2014;24:766–9.
Wan Y, Maurer M, He H-Z, Xia Y-Q, Hao S-J, Zhang W-L, et al. Enrichment of extracellular vesicles with lipid nanoprobe functionalized nanostructured silica. Lab Chip. 2019;19:2346–55.
Allenson Okay, Castillo J, San Lucas FA, Scelo G, Kim DU, Bernard V, et al. Excessive prevalence of mutantKRAS in circulating exosome-derived DNA from early-stage pancreatic most cancers sufferers. Ann Oncol. 2017;28:741–7.
Bernard V, Kim DU, San Lucas FA, Castillo J, Allenson Okay, Mulu FC, et al. Circulating Nucleic Acids Are Related With Outcomes of Sufferers With Pancreatic Most cancers. Gastroenterology. 2019; 156: 108 – 18.e4.
San Lucas FA, Allenson Okay, Bernard V, Castillo J, Kim DU, Ellis Okay, et al. Minimally invasive genomic and transcriptomic profiling of visceral cancers by next-generation sequencing of circulating exosomes. Ann Oncol. 2016;27:635–41.
Yang S, Che SPY, Kurywchak P, Tavormina JL, Gansmo LB, Correa de Sampaio P, et al. Detection of mutant KRAS and TP53 DNA in circulating exosomes from wholesome people and sufferers with pancreatic most cancers. Most cancers Biol Ther. 2017;18:158–65.
Yamamoto H, Watanabe Y, Oikawa R, Morita R, Yoshida Y, Maehata T, et al. BARHL2Methylation Utilizing Gastric Wash DNA or Gastric Juice Exosomal DNA is a Helpful Marker For Early Detection of Gastric Most cancers in anH. pylori-Impartial Method. Clin Translational Gastroenterol. 2016;7:e184.
ExoCarta. http://wwwexocartaorg/. Accessed 20 August 2022.
Wu H, Chen X, Ji J, Zhou R, Liu J, Ni W, et al. Progress of Exosomes within the Analysis and Remedy of Pancreatic Most cancers. Genetic Take a look at Mol biomarkers. 2019;23:215–22.
Yang KS, Im H, Hong S, Pergolini I, Del Castillo AF, Wang R, et al. Multiparametric plasma EV profiling facilitates prognosis of pancreatic malignancy. Sci Transl Med. 2017;9:eaal3226.
Melo SA, Luecke LB, Kahlert C, Fernandez AF, Gammon ST, Kaye J, et al. Glypican-1 identifies most cancers exosomes and detects early pancreatic most cancers. Nature. 2015;523:177–82.
Jin H, Liu P, Wu Y, Meng X, Wu M, Han J, et al. Exosomal zinc transporter ZIP4 promotes most cancers progress and is a novel diagnostic biomarker for pancreatic most cancers. Most cancers Sci. 2018;109:2946–56.
Liu C, Zhao J, Tian F, Cai L, Zhang W, Feng Q, et al. Low-cost thermophoretic profiling of extracellular-vesicle floor proteins for the early detection and classification of cancers. Nat Biomedical Eng. 2019;3:183–93.
Frampton AE, Prado MM, López-Jiménez E, Fajardo-Puerta AB, Jawad ZAR, Lawton P, et al. Glypican-1 is enriched in circulating-exosomes in pancreatic most cancers and correlates with tumor burden. Oncotarget. 2018;9:19006–13.
Giampieri R, Piva F, Occhipinti G, Bittoni A, Righetti A, Pagliaretta S, et al. Medical influence of various exosomes’ protein expression in pancreatic ductal carcinoma sufferers handled with customary first line palliative chemotherapy. PLoS ONE. 2019;14:e0215990.
Liang Okay, Liu F, Fan J, Solar D, Liu C, Lyon CJ, et al. Nanoplasmonic Quantification of Tumor-derived Extracellular Vesicles in Plasma Microsamples for Analysis and Remedy Monitoring. Nat Biomed Eng. 2017;1:0021.
Ferguson S, Yang KS, Zelga P, Liss AS, Carlson JC, Del Castillo CF, et al. Single-EV evaluation (sEVA) of mutated proteins permits detection of stage 1 pancreatic most cancers. Sci Adv. 2022;8:eabm3453.
Lennon KM, Wakefield DL, Maddox AL, Brehove MS, Willner AN, Garcia-Mansfield Okay, et al. Single molecule characterization of particular person extracellular vesicles from pancreatic most cancers. J Extracell Vesicles. 2019;8:1685634.
Lewis JM, Vyas AD, Qiu Y, Messer KS, Heller MJJAN. Built-in Evaluation of Exosomal Protein Biomarkers on Alternating Present Electrokinetic Chips Permits Fast Detection of Pancreatic Most cancers in Affected person Blood. 2018; 12: 3311–20.
Zhang W, Wang L, Li D, Campbel DH, Walsh BJ, Packer NH, et al. Phenotypic profiling of pancreatic ductal adenocarcinoma plasma-derived small extracellular vesicles for most cancers prognosis and most cancers stage prediction: a proof-of-concept research. Anal Strategies. 2022;14:2255–65.
Dong C, Huang L, Melo SA, Kurywchak P, Peng Q, Kahlert C, et al. A number of antibodies establish glypican-1 related to exosomes from pancreatic most cancers cells and serum from sufferers with pancreatic most cancers. bioRxiv; 2018: 145706.
Moutinho-Ribeiro P, Adem B, Batista I, Silva M, Silva S, Ruivo CF, et al. Exosomal glypican-1 discriminates pancreatic ductal adenocarcinoma from power pancreatitis. Dig Liver Illness. 2022;54:871–7.
Lux A, Kahlert C, Grützmann R, Pilarsky C. c-Met and PD-L1 on Circulating Exosomes as Diagnostic and Prognostic Markers for Pancreatic Most cancers. Int J Mol Sci. 2019;20:3305.
Kimura H, Yamamoto H, Harada T, Fumoto Okay, Osugi Y, Sada R, et al. CKAP4, a DKK1 Receptor, Is a Biomarker in Exosomes Derived from Pancreatic Most cancers and a Molecular Goal for Remedy. Clin Most cancers Res. 2019;25:1936–47.
Leca J, Martinez S, Lac S, Nigri J, Secq V, Rubis M, et al. Most cancers-associated fibroblast-derived annexin A6 + extracellular vesicles assist pancreatic most cancers aggressiveness. J Clin Investig. 2016;126:4140–56.
Odaka H, Hiemori Okay, Shimoda A, Akiyoshi Okay, Tateno H. CD63-positive extracellular vesicles are potential diagnostic biomarkers of pancreatic ductal adenocarcinoma. BMC Gastroenterol. 2022;22:153.
Xie Z, Gao Y, Ho C, Li L, Jin C, Wang X, et al. Exosome-delivered CD44v6/C1QBP advanced drives pancreatic most cancers liver metastasis by selling fibrotic liver microenvironment. Intestine. 2022;71:568–79.
Li J, Li Y, Chen S, Duan W, Kong X, Wang Y, et al. Extremely Delicate Exosome Detection for Early Analysis of Pancreatic Most cancers Utilizing Immunoassay Based mostly on Hierarchical Floor-Enhanced Raman Scattering Substrate. Small Strategies. 2022;6:2200154.
Asada T, Nakahata S, Fauzi YR, Ichikawa T, Inoue Okay, Shibata N, et al. Integrin α6A (ITGA6A)-type Splice Variant in Extracellular Vesicles Has a Potential as a Novel Marker of the Early Recurrence of Pancreatic Most cancers. Anticancer Res. 2022;42:1763.
Osteikoetxea X, Benke M, Rodriguez M, Pálóczi Okay, Sódar BW, Szvicsek Z, et al. Detection and proteomic characterization of extracellular vesicles in human pancreatic juice. Biochem Biophys Res Commun. 2018;499:37–43.
Zheng J, Hernandez JM, Doussot A, Bojmar L, Zambirinis CP, Costa-Silva B, et al. Extracellular matrix proteins and carcinoembryonic antigen-related cell adhesion molecules characterize pancreatic duct fluid exosomes in sufferers with pancreatic most cancers. HPB. 2018;20:597–604.
Buscail E, Chauvet A, Quincy P, Degrandi O, Buscail C, Lamrissi I, et al. CD63-GPC1-Constructive Exosomes Coupled with CA19-9 Supply Good Diagnostic Potential for Resectable Pancreatic Ductal Adenocarcinoma. Translational Oncol. 2019;12:1395–403.
Hinestrosa JP, Lewis JM, Balcer HI, Kurzrock R, Lippman S, Krishnan R. Summary 5960: Blood-based extracellular vesicle biomarker check for detection of early-stage pancreatic most cancers. Most cancers Res. 2022;82:5960.
Inoue H, Eguchi A, Kobayashi Y, Usugi E, Yamada R, Tsuboi J, et al. Extracellular vesicles from pancreatic ductal adenocarcinoma endoscopic ultrasound-fine needle aspiration samples include a protein barcode. J Hepato-Biliary-Pancreat Sci. 2022;29:394–403.
Donoso-Quezada J, Ayala-Mar S, González-Valdez J. The function of lipids in exosome biology and intercellular communication: Perform, analytics and purposes. 2021; 22: 204 – 20.
Report M, Carayon Okay, Poirot M, Silvente-Poirot S. Exosomes as new vesicular lipid transporters concerned in cell-cell communication and varied pathophysiologies. Biochim Biophys Acta. 2014;1841:108–20.
Skotland T, Ekroos Okay, Kauhanen D, Simolin H, Seierstad T, Berge V, et al. Molecular lipid species in urinary exosomes as potential prostate most cancers biomarkers. European journal of most cancers (Oxford, England: 1990). 2017; 70: 122 – 32.
Fan TWM, Zhang X, Wang C, Yang Y, Kang W-Y, Arnold S, et al. Exosomal lipids for classifying early and late stage non-small cell lung most cancers. Anal Chim Acta. 2018;1037:256–64.
Eylem CC, Yilmaz M, Derkus B, Nemutlu E, Camci CB, Yilmaz E, et al. Untargeted multi-omic evaluation of colorectal cancer-specific exosomes reveals joint pathways of colorectal most cancers in each scientific samples and cell tradition. Most cancers Lett. 2020;469:186–94.
Sharma R, Huang X, Brekken RA, Schroit AJ. Detection of phosphatidylserine-positive exosomes for the prognosis of early-stage malignancies. Br J Most cancers. 2017;117:545–52.
Linton SS, Abraham T, Liao J, Clawson GA, Butler PJ, Fox T, et al. Tumor-promoting results of pancreatic most cancers cell exosomes on THP-1-derived macrophages. PLoS ONE. 2018;13:e0206759.
Hinzman CP, Singh B, Bansal S, Li Y, Iliuk A, Girgis M, et al. A multi-omics method identifies pancreatic most cancers cell extracellular vesicles as mediators of the unfolded protein response in regular pancreatic epithelial cells. J Extracell Vesicles. 2022;11:e12232.
Tao L, Zhou J, Yuan C, Zhang L, Li D, Si D, et al. Metabolomics identifies serum and exosomes metabolite markers of pancreatic most cancers. Metabolomics. 2019;15:86.
Chen Y, Ding L, Ju H. In Situ Mobile Glycan Evaluation. Acc Chem Res. 2018;51:890–9.
Scott E, Munkley J. Glycans as Biomarkers in Prostate Most cancers. Int J Mol Sci. 2019;20:1389.
Díaz-Fernández A, Miranda-Castro R, de-los-Santos-Álvarez N, Lobo-Castañón MJ, Estrela P. Impedimetric aptamer-based glycan PSA rating for discrimination of prostate most cancers from different prostate illnesses. Biosens Bioelectron. 2021;175:112872.
Munkley J. The glycosylation panorama of pancreatic most cancers (Overview). Oncol Lett. 2019;17:2569–75.
Engle DD, Tiriac H, Rivera KD, Pommier A, Whalen S, Oni TE, et al. The glycan CA19-9 promotes pancreatitis and pancreatic most cancers in mice. Science. 2019;364:1156–62.
Yokose T, Kabe Y, Matsuda A, Kitago M, Matsuda S, Hirai M, et al. O-Glycan-Altered Extracellular Vesicles: A Particular Serum Marker Elevated in Pancreatic Most cancers. Cancers. 2020;12:2469.
Choi Y, Park U, Koo H-J, Park J-s, Lee DH, Kim Okay, et al. Exosome-mediated prognosis of pancreatic most cancers utilizing lectin-conjugated nanoparticles sure to selective glycans. Biosens Bioelectron. 2021;177:112980.
Tutrone R, Donovan MJ, Torkler P, Tadigotla V, McLain T, Noerholm M, et al. Medical utility of the exosome based mostly ExoDx Prostate(IntelliScore) EPI check in males presenting for preliminary Biopsy with a PSA 2–10 ng/mL. Prostate Most cancers Prostatic Dis. 2020;23:607–14.
Enderle D, Noerholm M. Are extracellular vesicles prepared for the scientific laboratory? LaboratoriumsMedizin. 2022.
Becker A, Thakur BK, Weiss JM, Kim HS, Peinado H, Lyden D. Extracellular Vesicles in Most cancers: Cell-to-Cell Mediators of Metastasis. Most cancers Cell. 2016;30:836–48.
Pullan JE, Confeld MI, Osborn JK, Kim J, Sarkar Okay, Mallik S. Exosomes as Drug Carriers for Most cancers Remedy. Mol Pharm. 2019;16:1789–98.
Richards KE, Zeleniak AE, Fishel ML, Wu J, Littlepage LE, Hill R. Most cancers-associated fibroblast exosomes regulate survival and proliferation of pancreatic most cancers cells. Oncogene. 2017;36:1770–8.
Xiao W, Pahlavanneshan M, Eun C-Y, Zhang X, DeKalb C, Mahgoub B, et al. Matrix stiffness mediates pancreatic most cancers chemoresistance via induction of exosome hypersecretion in a most cancers related fibroblasts-tumor organoid biomimetic mannequin. Matrix Biology Plus. 2022;14:100111.
Mikamori M, Yamada D, Eguchi H, Hasegawa S, Kishimoto T, Tomimaru Y, et al. MicroRNA-155 Controls Exosome Synthesis and Promotes Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma. Sci Rep. 2017;7:42339.
Richards KE, Xiao W, Hill R, Workforce obotUPR. Most cancers-Related Fibroblasts Confer Gemcitabine Resistance to Pancreatic Most cancers Cells via PTEN-Focusing on miRNAs in Exosomes. Cancers. 2022;14:2812.
Hoshino A, Costa-Silva B, Shen T-L, Rodrigues G, Hashimoto A, Tesic Mark M, et al. Tumour exosome integrins decide organotropic metastasis. Nature. 2015;527:329–35.
Wang C-A, Chang I-H, Hou P-C, Tai Y-J, Li W-N, Hsu P-L, et al. DUSP2 regulates extracellular vesicle-VEGF-C secretion and pancreatic most cancers early dissemination. J Extracell vesicles. 2020;9:1746529.
Li Y-J, Wu J-Y, Wang J-M, Hu X-B, Cai J-X, Xiang D-X. Gemcitabine loaded autologous exosomes for efficient and protected chemotherapy of pancreatic most cancers. Acta Biomater. 2020;101:519–30.
Aspe JR, Diaz Osterman CJ, Jutzy JMS, Deshields S, Whang S, Wall NR. Enhancement of Gemcitabine sensitivity in pancreatic adenocarcinoma by novel exosome-mediated supply of the Survivin-T34A mutant. J Extracell Vesicles. 2014;3:23244.
Al Faruque H, Choi E-S, Kim J-H, Kim E. Enhanced impact of autologous EVs delivering paclitaxel in pancreatic most cancers. J Managed Launch. 2022;347:330–46.
Xu L, Faruqu FN, Lim YM, Lim KY, Liam-Or R, Walters AA, et al. Exosome-mediated RNAi of PAK4 prolongs survival of pancreatic most cancers mouse mannequin after loco-regional remedy. Biomaterials. 2021;264:120369.
Han S, Gonzalo DH, Feely M, Rinaldi C, Belsare S, Zhai H, et al. Stroma-derived extracellular vesicles ship tumor-suppressive miRNAs to pancreatic most cancers cells. Oncotarget. 2018;9:5764.
Que R-s, Lin C, Ding G-p, Wu Z-r. Cao L-p. Growing the immune exercise of exosomes: the impact of miRNA-depleted exosome proteins on activating dendritic cell/cytokine-induced killer cells towards pancreatic most cancers. J Zhejiang College-SCIENCE B. 2016;17:352–60.
Gastpar R, Gehrmann M, Bausero MA, Asea A, Gross C, Schroeder JA, et al. Warmth shock protein 70 surface-positive tumor exosomes stimulate migratory and cytolytic exercise of pure killer cells. Most cancers Res. 2005;65:5238–47.
Zech D, Rana S, Büchler MW, Zöller M. Tumor-exosomes and leukocyte activation: an ambivalent crosstalk. Cell Communication and Signaling. 2012;10:37.
Mahmoodzadeh Hosseini H, Ali Imani Fooladi A, Soleimanirad J, Reza Nourani M, Mahdavi M. Exosome/staphylococcal enterotoxin B, an anti tumor compound towards pancreatic most cancers. J BUON. 2014;19:440–8.
Zhou W, Chen X, Zhou Y, Shi S, Liang C, Yu X, et al. Exosomes derived from immunogenically dying tumor cells as a flexible instrument for vaccination towards pancreatic most cancers. Biomaterials. 2022;280:121306.
Lau C, Kim Y, Chia D, Spielmann N, Eibl G, Elashoff D, et al. Function of pancreatic cancer-derived exosomes in salivary biomarker improvement. J Biol Chem. 2013;288:26888–97.
Wang M, Su Z, Amoah Barnie P. Crosstalk amongst colon cancer-derived exosomes, fibroblast-derived exosomes, and macrophage phenotypes in colon most cancers metastasis. Int Immunopharmacol. 2020;81:106298.
Binenbaum Y, Fridman E, Yaari Z, Milman N, Schroeder A, Ben David G, et al. Switch of miRNA in Macrophage-Derived Exosomes Induces Drug Resistance in Pancreatic Adenocarcinoma. Most cancers Res. 2018;78:5287.
Ostenfeld MS, Jeppesen DK, Laurberg JR, Boysen AT, Bramsen JB, Primdal-Bengtson B, et al. Mobile Disposal of miR23b by RAB27-Dependent Exosome Launch Is Linked to Acquisition of Metastatic Properties. Most cancers Res. 2014;74:5758.
Fares J, Kashyap R, Zimmermann P. Syntenin. Key participant in most cancers exosome biogenesis and uptake? Cell Adhes Migr. 2017;11:124–6.
Christianson HC, Svensson KJ, van Kuppevelt TH, Li J-P, Belting M. Most cancers cell exosomes rely on cell-surface heparan sulfate proteoglycans for his or her internalization and purposeful exercise. Proceedings of the Nationwide Academy of Sciences. 2013; 110: 17380.
Hao Y, Music H, Zhou Z, Chen X, Li H, Zhang Y, et al. Promotion or inhibition of extracellular vesicle launch: Rising therapeutic alternatives. J Managed Launch. 2021;340:136–48.
Rezaie J, Akbari A, Rahbarghazi R. Inhibition of extracellular vesicle biogenesis in tumor cells: A doable technique to scale back tumorigenesis. Cell Biochem Funct. 2022;40:248–62.
Catalano M, O’Driscoll L. Inhibiting extracellular vesicles formation and launch: a overview of EV inhibitors. J Extracell vesicles. 2020;9:1703244.
Rosenfeldt MT, O’Prey J, Flossbach L, Nixon C, Morton JP, Sansom OJ, et al. PTEN deficiency permits the formation of pancreatic most cancers within the absence of autophagy. Cell Loss of life & Differentiation. 2017;24:1303–4.
Si W, Liu X, Wei R, Zhang Y, Zhao Y, Cui L, et al. MTA2-mediated inhibition of PTEN results in pancreatic ductal adenocarcinoma carcinogenicity. Cell Loss of life Dis. 2019;10:206.
Capello M, Vykoukal JV, Katayama H, Bantis LE, Wang H, Kundnani DL, et al. Exosomes harbor B cell targets in pancreatic adenocarcinoma and exert decoy operate towards complement-mediated cytotoxicity. Nat Commun. 2019;10:254.
Vader P, Mol EA, Pasterkamp G, Schiffelers RM. Extracellular vesicles for drug supply. Adv Drug Deliv Rev. 2016;106:148–56.
Kamerkar S, LeBleu VS, Sugimoto H, Yang S, Ruivo CF, Melo SA, et al. Exosomes facilitate therapeutic focusing on of oncogenic KRAS in pancreatic most cancers. Nature. 2017;546:498–503.
Kim MS, Haney MJ, Zhao Y, Mahajan V, Deygen I, Klyachko NL, et al. Growth of exosome-encapsulated paclitaxel to beat MDR in most cancers cells. Nanomed Nanotechnol Biol Med. 2016;12:655–64.
Lamichhane TN, Jeyaram A, Patel DB, Parajuli B, Livingston NK, Arumugasaamy N, et al. Oncogene Knockdown by way of Energetic Loading of Small RNAs into Extracellular Vesicles by Sonication. Cell Mol Bioeng. 2016;9:315–24.
Rahbarghazi R, Jabbari N, Sani NA, Asghari R, Salimi L, Kalashani SA, et al. Tumor-derived extracellular vesicles: dependable instruments for Most cancers prognosis and scientific purposes. Cell Communication and Signaling. 2019;17:1–17.
Fais S, O’Driscoll L, Borras FE, Buzas E, Camussi G, Cappello F, et al. Proof-Based mostly Medical Use of Nanoscale Extracellular Vesicles in Nanomedicine. ACS Nano. 2016;10:3886–99.
Walker S, Busatto S, Pham A, Tian M, Suh A, Carson Okay, et al. Extracellular vesicle-based drug supply programs for most cancers remedy. Theranostics. 2019;9:8001.
Surana R, LeBleu VS, Lee JJ, Smaglo BG, Zhao D, Lee MS, et al. Part I research of mesenchymal stem cell (MSC)-derived exosomes with KRASG12D siRNA in sufferers with metastatic pancreatic most cancers harboring a KRASG12D mutation. J Clin Oncol. 2022;40:TPS633-TPS.
Ou Y-H, Liang J, Czarny B, Wacker MG, Yu V, Wang J-W, et al. Extracellular Vesicle (EV) biohybrid programs for most cancers remedy: Current advances and future views. Seminars in Most cancers Biology: Elsevier; 2021. p.45–61.
Xu L, Faruqu FN, Liam-Or R, Abu Abed O, Li D, Venner Okay, et al. Design of experiment (DoE)-driven in vitro and in vivo uptake research of exosomes for pancreatic most cancers supply enabled by copper-free click on chemistry-based labelling. J Extracell vesicles. 2020;9:1779458.
Xavier CP, Castro I, Caires HR, Ferreira D, Cavadas B, Pereira L, et al. Chitinase 3-like-1 and fibronectin within the cargo of extracellular vesicles shed by human macrophages affect pancreatic most cancers mobile response to gemcitabine. Most cancers Lett. 2021;501:210–23.
Gilligan KE, Dwyer RM. Engineering exosomes for most cancers remedy. Int J Mol Sci. 2017;18:1122.
Liang Y, Duan L, Lu J, Xia J. Engineering exosomes for focused drug supply. Theranostics. 2021;11:3183–95.
Dai S, Wei D, Wu Z, Zhou X, Wei X, Huang H, et al. Part I scientific trial of autologous ascites-derived exosomes mixed with GM-CSF for colorectal most cancers. Mol Ther. 2008;16:782–90.
Guo M, Wu F, Hu G, Chen L, Xu J, Xu P, et al. Autologous tumor cell–derived microparticle-based focused chemotherapy in lung most cancers sufferers with malignant pleural effusion. Sci Transl Med. 2019;11:eaat5690.
Ma J, Zhang Y, Tang Okay, Zhang H, Yin X, Li Y, et al. Reversing drug resistance of sentimental tumor-repopulating cells by tumor cell-derived chemotherapeutic microparticles. Cell Res. 2016;26:713–27.
Tang Okay, Zhang Y, Zhang H, Xu P, Liu J, Ma J, et al. Supply of chemotherapeutic medicine in tumour cell-derived microparticles. Nat Commun. 2012;3:1282.
Meng W, He C, Hao Y, Wang L, Li L, Zhu G. Prospects and challenges of extracellular vesicle-based drug supply system: Contemplating cell supply. Drug Supply. 2020;27:585–98.
Yamashita T, Takahashi Y, Takakura Y. Risk of exosome-based therapeutics and challenges in manufacturing of exosomes eligible for therapeutic utility. Biol Pharm Bull. 2018;41:835–42.
de Almeida Fuzeta M, Bernardes N, Oliveira FD, Costa AC, Fernandes-Platzgummer A, Farinha JP, et al. Scalable manufacturing of human mesenchymal stromal cell-derived extracellular vesicles underneath serum-/xeno-free circumstances in a microcarrier-based bioreactor tradition system. Entrance cell Dev biology. 2020;8:553444.
Yi YW, Lee JH, Kim S-Y, Pack C-G, Ha DH, Park SR, et al. Advances in evaluation of biodistribution of exosomes by molecular imaging. Int J Mol Sci. 2020;21:665.
Solar H, Shi Okay, Qi Okay, Kong H, Zhang J, Dai S, et al. Pure Killer Cell-Derived Exosomal miR-3607-3p Inhibits Pancreatic Most cancers Development by Focusing on IL-26. Entrance Immunol. 2019;10:2819.
Shang S, Wang J, Chen S, Tian R, Zeng H, Wang L, et al. Exosomal miRNA-1231 derived from bone marrow mesenchymal stem cells inhibits the exercise of pancreatic most cancers. Most cancers Med. 2019;8:7728–40.
Huber M, Brehm CU, Gress TM, Buchholz M, Alashkar Alhamwe B, von Strandmann EP, et al. The Immune Microenvironment in Pancreatic Most cancers. Int J Mol Sci. 2020;21:7307.
Hofmann L, Ludwig S, Vahl JM, Brunner C, Hoffmann TK, Theodoraki M-N. The Rising Function of Exosomes in Analysis, Prognosis, and Remedy in Head and Neck Most cancers. Int J Mol Sci. 2020;21:4072.
Whiteside TL. Exosomes and tumor-mediated immune suppression. J Clin Investig. 2016;126:1216–23.
Solar W, Luo J-d, Jiang H, Duan DD. Tumor exosomes: a double-edged sword in most cancers remedy. Acta Pharmacol Sin. 2018;39:534–41.
Gehrmann U, Näslund TI, Hiltbrunner S, Larssen P, Gabrielsson S. Harnessing the exosome-induced immune response for most cancers immunotherapy. Sem Most cancers Biol. 2014;28:58–67.
Gu X, Erb U, Büchler MW, Zöller M. Improved vaccine efficacy of tumor exosome in comparison with tumor lysate loaded dendritic cells in mice. Int J Most cancers. 2015;136:E74–84.
Koyama Y, Ito T, Hasegawa A, Eriguchi M, Inaba T, Ushigusa T, et al. Exosomes derived from tumor cells genetically modified to precise Mycobacterium tuberculosis antigen: a novel vaccine for most cancers remedy. Biotechnology letters. 2016; 38: 1857–66.
